CMS Launches GENEROUS Model to Implement Most-Favored-Nation Pricing for Medicaid Prescription Drugs
Key Insights
The Centers for Medicare & Medicaid Services (search) announced the GENEROUS Model, a voluntary pilot program launching in 2026 that will allow participating state Medicaid (search) programs to purchase select drugs at prices aligned with those paid in other developed countries.
The initiative aims to address rising Medicaid (search) prescription drug spending, which exceeded $100 billion in 2024 and represents a $10 billion increase from 2022 figures.
Under the five-year model, CMS will negotiate lower prices with participating manufacturers through supplemental rebates, while states implement uniform coverage criteria to ensure predictable patient access.
The Centers for Medicare & Medicaid Services (search) (CMS) announced the GENErating cost Reductions fOr U.S. Medicaid (search) (GENEROUS) Model, a landmark initiative designed to significantly reduce prescription drug costs for state Medicaid programs through most-favored-nation pricing mechanisms. The voluntary pilot program, set to launch in January 2026, represents a major policy shift aimed at aligning U.S. Medicaid drug prices with those paid in other developed countries.
Program Structure and Implementation
The GENEROUS model will operate as a five-year voluntary pilot program that builds upon the existing Medicaid (search) Drug Rebate Program (MDRP) and the Cell and Gene Therapy Access Model. Under this framework, participating manufacturers will adjust their prices through supplemental rebates to participating states, effectively bringing Medicaid pricing in line with international standards.
"The GENEROUS Model will help ensure state Medicaid (search) programs are paying a fair and reasonable price for prescription drugs—furthering our efforts to preserve funds for our most vulnerable," said CMS Administrator Dr. Mehmet Oz.
The model establishes a structured approach where CMS will negotiate prices directly with interested drug manufacturers, while participating states implement standardized, transparent coverage criteria. States will invoice manufacturers for supplemental rebates, with CMS monitoring payment accuracy and sharing rebates through reductions in the federal share of Medicaid (search) payments.
Financial Impact and Market Context
The initiative addresses mounting financial pressures within the Medicaid (search) system, where prescription drug spending has reached unprecedented levels. In 2024, total gross Medicaid spending on prescription drugs exceeded $100 billion, representing a $10 billion increase from 2022 figures. After accounting for existing manufacturer rebates, net Medicaid spending totaled $60 billion.
"Drug prices in the US remain far too high," stated CMS Innovation Center Director Abe Sutton. "GENEROUS aims to ensure that Medicaid (search) pricing will be on par with those in other developed nations. My hope is that all eligible Medicaid programs choose to participate in the pilot to help ensure that their Medicaid dollars can go further to support those in need."
Administrative Framework and Timeline
CMS plans to release a Request for Applications (RFA) for drug manufacturers later this fall, concurrent with soliciting letters of intent from state Medicaid (search) agencies interested in program participation. States expressing initial interest will subsequently have the opportunity to formally apply and potentially opt into the terms and prices negotiated with participating manufacturers.
The standardized coverage criteria negotiated between CMS and manufacturers are designed to provide patients and healthcare providers with predictable access across all participating states, addressing current variability in Medicaid (search) coverage policies.
Policy Context and Leadership Support
The GENEROUS model represents the latest in a series of Trump administration initiatives targeting high prescription drug prices. The announcement follows recent drug pricing agreements with major pharmaceutical companies including Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly and Company, as part of the broader TrumpRx initiative.
"Thanks to President Trump's leadership and Dr. Oz's bold direction at CMS, we're expanding access to affordable medicines for millions of Americans," said Health and Human Services Secretary Robert F. Kennedy, Jr. "By bringing most-favored-nation pricing to Medicaid (search), we're driving down drug costs and protecting the future of care for our most vulnerable citizens."
The model's implementation reflects broader administrative efforts to control healthcare costs and ensure that U.S. drug prices align with global standards, particularly for programs serving vulnerable populations through the Medicaid (search) system.